Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Glatiramer acetate controlled release - Mapi Pharma

Next Previous
Drug Profile

Glatiramer acetate controlled release - Mapi Pharma

Alternative Names: GA Depot; GA Depot injection; GA long-acting injection; Glatiramer acetate depot formulation - Mapi Pharma; Glatiramer acetate long-acting formulation - Mapi Pharma; Glatiramer acetate microspheres

Latest Information Update: 02 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mapi Pharma
  • Class Peptides; Polymers
  • Mechanism of Action Immunomodulators; MHC class II gene modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Multiple sclerosis

Most Recent Events

  • 27 Feb 2025 Updated efficacy and adverse data from a phase II trial in Multiple sclerosis presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum (ACTRIMS-2025)
  • 13 Apr 2024 Adverse event data from a phase III trial in Multiple sclerosis presented at the 76th Annual Meeting of the American Academy of Neurology 2024 (AAN-2024)
  • 11 Mar 2024 Viatris and Mapi Pharma receives complete response letter from the US FDA for Glatiramer acetate controlled release in Multiple sclerosis

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top